ArticleCommunications medicine2026
Neuropsychiatric association of tirzepatide and semaglutide in obesity with and without type 2 diabetes.
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuropsychiatric outcomes after starting newer anti-obesity medicines remain uncertain in routine care. We evaluate associations between initiation of tirzepatide or semaglutide and incident neuropsychiatric diagnoses in people with obesity, stratified by type 2 diabetes (T2D).
methodsUsing a United States electronic health record network (2020-2025), we identified adults with obesity who newly started tirzepatide or semaglutide and matched them one-to-one to new users of naltrexone-bupropion, phentermine, or phentermine-topiramate. We modeled the time to first recorded diagnosis over 24 months; bariatric surgery recipients were examined as a contextual comparator. Confidence intervals are 95%.
resultsHere we show that, versus naltrexone-bupropion, semaglutide is associated with lower hazards of anxiety disorder in adults with T2D (hazard ratio 0.67, 0.51-0.87) and without T2D (0.73, 0.64-0.83), and lower hazards of depression in both strata (with T2D: 0.69, 0.50-0.95; without T2D: 0.53, 0.45-0.61). Tirzepatide versus naltrexone-bupropion is associated with lower hazard ratios for anxiety disorder (with T2D: 0.55, 0.40-0.76; without T2D: 0.78, 0.68-0.89) and depression (with T2D: 0.49, 0.33-0.72; without T2D: 0.57, 0.49-0.66). In adults without T2D, tirzepatide versus semaglutide is associated with higher hazards of anxiety disorder (1.12, 1.06-1.18) and insomnia (1.13, 1.05-1.21).
conclusionsInitiation of tirzepatide and semaglutide is associated with differing hazard patterns across prescription comparators, with bariatric surgery providing additional context. These findings inform monitoring and shared decisions, while remaining subject to residual confounding and diagnosis misclassification.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.